Company registration number 12207217 (England and Wales)
REMO DENTAL LABORATORY LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
REMO DENTAL LABORATORY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 9
REMO DENTAL LABORATORY LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
343,103
323,163
Current assets
Debtors
5
263,161
218,581
Cash at bank and in hand
82,757
131,881
345,918
350,462
Creditors: amounts falling due within one year
6
(227,131)
(306,692)
Net current assets
118,787
43,770
Total assets less current liabilities
461,890
366,933
Creditors: amounts falling due after more than one year
7
(171,675)
(132,006)
Provisions for liabilities
(67,609)
(78,416)
Net assets
222,606
156,511
Capital and reserves
Called up share capital
200
200
Profit and loss reserves
9
222,406
156,311
Total equity
222,606
156,511
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 20 May 2026 and are signed on its behalf by:
Mr N Bonnard
Director
Company registration number 12207217 (England and Wales)
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information
Remo Dental Laboratory Limited is a private company limited by shares incorporated in England and Wales. The registered office is First Floor, 1 Des Roches Square, Witan Way, Witney, OX28 4BE.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.
The financial statements of the company are consolidated in the financial statements of Corus Europe B.V.. These consolidated financial statements are available from its registered office, Spoetnik 30, 3824 MG Amersfoort, Netherlands.
1.2
Revenue
Turnover represents amounts receivable for goods supplied and services rendered in the ordinary course of business, net of VAT, trade discounts and returns.
Revenue from clinical dentistry and other dental services is recognised when the service has been performed.
Revenue from dental laboratory work is recognised when the customised product is completed and delivered to the customer. Revenue from the sale of stock items is recognised when goods are delivered, and the risks and rewards of ownership have transferred to the customer.
1.3
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
25% reducing balance
Fixtures and fittings
20% reducing balance
Computers
25% straight line
Motor vehicles
25% reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.4
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.5
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.6
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.7
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.8
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.9
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.10
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.11
Leases
As lessee
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
The principal areas in which estimates are applied are as follows:
Useful economic lives of tangible fixed assets
The annual depreciation charge for tangible fixed assets is sensitive to changes in the estimated useful economic lives and residual values of those assets. Useful lives and residual values are reviewed annually and amended where necessary.
Recoverability of trade debtors
The company makes an estimate of the recoverable value of trade debtors. Provisions are made where there is objective evidence that amounts due may not be collected in full. The level of provision is based on factors including the age of balances, historical collection experience and specific customer circumstances.
Revenue recognition
Judgement may be required in determining the appropriate timing of recognition of revenue from dental laboratory sales, particularly where work is incomplete at the year end or where adjustments are subsequently agreed with customers. Revenue is recognised when control of the goods has transferred and the amount can be measured reliably.
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Total
9
7
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024
448,444
Additions
127,093
Disposals
(11,561)
At 31 December 2024
563,976
Depreciation and impairment
At 1 January 2024
125,281
Depreciation charged in the year
98,543
Eliminated in respect of disposals
(2,951)
At 31 December 2024
220,873
Carrying amount
At 31 December 2024
343,103
At 31 December 2023
323,163
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
241,969
145,004
Amounts owed by group undertakings
(1,087)
Other debtors
21,192
74,664
263,161
218,581
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
38,977
61,946
Corporation tax
88,126
Other taxation and social security
16,903
38,545
Other creditors
83,125
206,201
227,131
306,692
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Other creditors
171,675
132,006
8
Audit report information
As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.
The auditor's report is unqualified and includes the following:
Opinion
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
Senior Statutory Auditor:
Mr Gary John McHale FCCA
Statutory Auditor:
DSA Prospect Audit Limited
Date of audit report:
21 May 2026
9
Profit and loss reserves
2024
2023
£
£
At the beginning of the year
156,311
136,157
Profit for the year
225,995
223,569
Dividends declared and paid in the year
(159,900)
(203,315)
Bonus issue charged to retained earnings
(100)
At the end of the year
222,406
156,311
10
Financial commitments, guarantees and contingent liabilities
The directors do not believe there are any financial commitments, guarantees or contingent liabilities that need to be disclosed.
11
Operating lease commitments
As lessee
REMO DENTAL LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
11
Operating lease commitments
(Continued)
- 9 -
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:
2024
2023
£
£
Total commitments
25,287
43,233
12
Events after the reporting date
There have been no significant post reporting date events.
13
Parent company
The parent company of Remo Dental Laboratory Limited is Corus Dent UK Limited.
As at the year end, the parent company of Corus Dent UK Limited was Corus Europe B.V. and its registered office is Spoetnik 30, 3824 MG Amersfoort, Netherlands.
As at the year end, the ultimate controlling party was Opera-Signadens S.A. and its registered office is Val Fleuri, L-1526, Luxembourg.
The company's financial statements are consolidated into the ultimate holding company's financial statements as at 31 December 2024 and are available from the parent's registered office.
Largest group
Opera-Signadens S.A.
Smallest group
Corus Europe B.V
2024-12-312024-01-01falsefalsefalse21 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr N BonnardMr J Ganderton122072172024-01-012024-12-31122072172024-12-31122072172023-12-3112207217core:OtherPropertyPlantEquipment2024-12-3112207217core:OtherPropertyPlantEquipment2023-12-3112207217core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3112207217core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3112207217core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3112207217core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3112207217core:CurrentFinancialInstruments2024-12-3112207217core:CurrentFinancialInstruments2023-12-3112207217core:ShareCapital2024-12-3112207217core:ShareCapital2023-12-3112207217core:RetainedEarningsAccumulatedLosses2024-12-3112207217core:RetainedEarningsAccumulatedLosses2023-12-3112207217core:RetainedEarningsAccumulatedLosses2023-12-3112207217core:RetainedEarningsAccumulatedLosses2022-12-3112207217bus:Director12024-01-012024-12-3112207217core:PlantMachinery2024-01-012024-12-3112207217core:FurnitureFittings2024-01-012024-12-3112207217core:ComputerEquipment2024-01-012024-12-3112207217core:MotorVehicles2024-01-012024-12-31122072172023-01-012023-12-3112207217core:OtherPropertyPlantEquipment2023-12-3112207217core:OtherPropertyPlantEquipment2024-01-012024-12-3112207217core:Non-currentFinancialInstruments2024-12-3112207217core:Non-currentFinancialInstruments2023-12-3112207217core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3112207217core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3112207217bus:PrivateLimitedCompanyLtd2024-01-012024-12-3112207217bus:FRS1022024-01-012024-12-3112207217bus:Audited2024-01-012024-12-3112207217bus:Director22024-01-012024-12-3112207217bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3112207217bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP